Document 0129
 DOCN  M9650129
 TI    A dose-ranging study of a prototype synthetic HIV-1MN V3 branched
       peptide vaccine. The National Institute of Allergy and Infectious
       Diseases AIDS Vaccine Evaluation Group.
 DT    9605
 AU    Gorse GJ; Keefer MC; Belshe RB; Matthews TJ; Forrest BD; Hsieh RH; Koff
       WC; Hanson CV; Dolin R; Weinhold KJ; Frey SE; Ketter N; Fast PE;
       Division of Infectious Diseases and Immunology, Saint Louis; University
       School of Medicine, Missouri 63110-0250, USA.
 SO    J Infect Dis. 1996 Feb;173(2):330-9. Unique Identifier : AIDSLINE
       MED/96162090
 AB    A phase I double-blind trial was done to examine the safety and
       immunogenicity of a prototype synthetic human immunodeficiency virus
       type 1 MN strain (HIV-1MN) third variable region domain (V3) branched
       peptide vaccine in HIV-1-uninfected healthy adult volunteers. Subjects
       were randomly assigned to receive 20, 100, or 500 micrograms of vaccine
       or alum adjuvant control on days 0, 28, and 168. The vaccine was
       well-tolerated and appeared safe. Induction of binding antibody to V3 MN
       branched peptide was vaccine dose-related and was detectable in 9 of 10
       subjects in the highest-vaccine-dose group. HIV-1MN-neutralizing
       antibody was detected after the third 500-micrograms dose in 8 of 10
       subjects at the 90% neutralization end point. V3 MN peptide stimulated
       lymphocyte proliferation in 15 (75%) of 20 subjects after vaccination.
       In conclusion, this prototype vaccine was safe and it induced humoral
       and cell-mediated immune responses.
 DE    Adult  Amino Acid Sequence  AIDS Vaccines/*ADMINISTRATION &
       DOSAGE/ADVERSE EFFECTS/IMMUNOLOGY  Dose-Response Relationship,
       Immunologic  Double-Blind Method  Enzyme-Linked Immunosorbent Assay
       Female  Human  HIV Antibodies/*ANALYSIS  HIV Envelope Protein
       gp120/CHEMISTRY/*IMMUNOLOGY  HIV-1/*IMMUNOLOGY  Lymphocyte
       Transformation  Male  Middle Age  Molecular Sequence Data
       Neutralization Tests  Peptide Fragments/CHEMISTRY/*IMMUNOLOGY  Support,
       Non-U.S. Gov't  Support, U.S. Gov't, P.H.S.  CLINICAL TRIAL  CLINICAL
       TRIAL, PHASE I  JOURNAL ARTICLE  MULTICENTER STUDY  RANDOMIZED
       CONTROLLED TRIAL

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).